Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD /

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are availabl...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Trifilieff, Alexandre (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Basel : Springer Basel : Imprint: Springer, 2014.
Edición:1st ed. 2014.
Colección:Milestones in Drug Therapy,
Temas:
Pharmacology.
Respiratory organs-Diseases.
Pneumology.
Acceso en línea:Texto Completo
Tabla de Contenidos:
  • Current Pharmacotherapy for COPD
  • The preclinical pharmacology of indacaterol
  • The design of the indacaterol molecule
  • The early clinical development of Indacaterol
  • INHANCE: An adaptive confirmatory study with dose selection at interim
  • Phase III clinical efficacy studies - lung function
  • Phase III Clinical Efficacy of Indacaterol
  • Patient-centered Outcomes
  • The history and performance of the Breezhaler device
  • What does the future hold for the therapy of COPD?  .

Ejemplares similares